Key Takeaways
- A poor quarter resets the year: Revenue and EBITDA fell sharply QoQ, and management revised its FY25 outlook from moderate growth to relatively flat, blaming the inherently lumpy nature of its CDMO and specialty GDS business.
- Gross margin compressed meaningfully: Gross margin dropped to 56.3% from 59.8% a year ago, driven by direct manufacturing costs, which flowed through to the EBITDA decline.
- The CMS pipeline is deepening, not just widening: Five to six new active CMS projects were added, two to three molecules sit one step from commercialization, and the CMS revenue share is expected to cross 50% in the next couple of years.
- Biosecure Act enthusiasm is being deliberately tempered: Management sees a highly favourable medium-term environment but has yet to see a material shift in RFPs or orders, and is calibrating capex to reality rather than rhetoric.
- What to watch next quarter: Whether the new production block in Unit 3 stays on track for FY26 commercial production, any evidence that Biosecure Act inquiries are converting to orders, and the pace of CMS molecule progression toward commercialization.
The Quarter: Lumpy by Design
- Revenue and EBITDA declined: The decrease in contribution versus Q2 FY24 drove the EBITDA fall, with the top line also slightly lower in H1 FY25 than H1 FY24.
- Gross margin hit: The 350 bps drop in gross margin to 56.3% was attributed to direct manufacturing costs, not mix shift or pricing pressure.
- Specialty GDS was the swing factor: The specialty business, primarily driven by Paliperidone, exhibited volatility this quarter, though management remains optimistic about the full year based on customers' expected growth.
- Prime segment held up on a few molecules: Mirtazapine, Levetiracetam and Escitalopram were strong products in the Prime segment, while others like Levetiracetam and Cipro have not grown much over a longer horizon.
- CMS commercial revenue held at ₹132 crores: Driven by commercial-segment molecules, with positive momentum expected to continue.
Saharsh Davuluri: "This quarter's performance has been poor, especially when compared with what we've been doing over the last several quarters. But as I mentioned earlier, it does reflect the lumpy volatile nature of our business."
CMS: The Engine Taking Share
- Five to six new active CMS projects added: The associated companies are two to three US biotechs; in one case projects moved from a Chinese CDMO to Neuland, and in another Neuland is organically setting up as the partner for clinical supplies, both in the CNS space.
- Two to three molecules are one step from commercialization: One in COPD and one in CNS are about a step away; management will update the table and commentary as milestones are achieved.
- CMS revenue share expected to cross 50%: Strong growth is anticipated in CMS over the next couple of years, though management declined to specify a mix ceiling.
- Biotech M&A is a net positive: Programs started with biotech companies are resulting in those companies being acquired by larger pharma, increasing the possibility of new business through the same account due to larger pipelines.
- FDA commercial approval for one NCE API: This increased the count of commercial APIs in the CMS table by one.
- Pricing on China-shift molecules is customer-led: For CMS molecules moving from China to India, biotech companies typically communicate a target price and Neuland works toward it; the data set is still small.
- Supplier status strategy is deliberate: Most innovators want at least two suppliers from a risk perspective; Neuland is part of the NDA filing and aims to be the key or primary supplier over time, which may or may not mean being the first supplier.
Biosecure Act: Rhetoric vs. Reality
- No material order shift yet: Management has yet to see significant impact by way of active RFPs or orders, though the environment remains highly favourable in the medium to long term.
- Capex is being calibrated to customer signals, not headlines: The company is engaging customers to understand how many projects are being outsourced, how many go to China, and how many come to India, to keep projections and related capex closer to reality.
- Indian capacity is mismatched to the opportunity: Capacities created in India during COVID were largely small-molecule API capacity tied to PLI schemes and India-China tensions, while Chinese CDMOs have a mix of small molecule, biologics and new modalities; new capabilities requiring investment in technology and scientific talent will be needed to capitalize on the Act.
- Economics will ultimately govern: Management believes any policies that constrict basic economics are not sustainable, and business will follow economics over time.
- China competition is not direct on Neuland's molecules: Neuland does not find too many Chinese competitors on its list of molecules on either the generic or CDMO side; China invested in large-scale manufacturing while Neuland invested in capability development, specific technology and specific IP.
Saharsh Davuluri: "We are in touch with our customers. We're engaging with them, finding out their preferences, how many projects are being outsourced, how many are going to China, how many come to India so that we keep our expectations, our projections and the related capital expenditure much closer to reality rather than get carried away by all the rhetoric that's happening in the market."
Capabilities & Competitive Positioning
- Neuland does not compete as a low-cost producer: The strategy is to focus on challenging technologies that differentiate the company and emphasize quality of business over quantity.
- Cost benchmarking is continuous: Neuland benchmarks costs globally across competitors in Europe and China and constantly invests in technology to stay competitive.
- Big pharma entry strategy has two paths: When existing CMS biotech customers get acquired by big pharma, Neuland uses that opportunity to build trust and expand business; the second path is acquiring unique technical capabilities not available in big pharma's existing network, such as peptides.
- Peptide pipeline is building: The team is working on Difelikefalin, with a DMF filing expected next year, and tirzepatide, a GLP-1, with a DMF filing hoped for the year after next.
- Scientific and manufacturing advisory boards help identify and recruit the right people through customer networks and the boards' own connections.
Sucheth Davuluri: "The way we see at least Neuland strategy play out in the future is that we want to focus more and more on technologies, which are challenging that will continue to differentiate Neuland that will help us continue to focus on the quality of business rather than the quantity of business."
Growth Roadmap: Near, Medium & Long Term
- FY26 is the rebound year: Management remains confident business will regain momentum from FY26, based on a significant order pipeline, strong customer demand, and the completion of additional manufacturing facilities this year coupled with anticipated commercial launches of CMS molecules.
- Near-term growth (1 to 2 years): Driven by DMFs already filed.
- Medium-term growth (3 years and beyond): Driven by new molecules including Difelikefalin, tirzepatide and other small molecules.
- New production block on track: The Unit 3 block is expected to be completed by FY25, with commercial production commencing in FY26.
- CMS portfolio breadth: Neuland has a portfolio of almost 80-plus projects on the CMS side.
- Customer depth over breadth: The growth strategy is to expand on the existing 25 to 30 deep customer relationships with innovator companies, while also focusing on technology.
Saharsh Davuluri: "I think it will be interesting to see how things play out, but we honestly believe that ultimately, the business is going to follow the economics of it. I think any kind of policies that will constrict basic economics are not going to be sustainable."
Margins & Mix
- EBITDA margin outlook is range-bound with a downside bias: If factors are very favourable, margins should approximate FY24 levels, which benefited from many tailwinds; otherwise they could come down a little bit.
- Business mix is not a reliable margin predictor: Management pushed back on the exercise of trying to figure out margins from the business mix, calling it not necessarily helpful.
- CMS share will rise but margins are not guided: While CMS is likely to go beyond 50% of revenue, management declined to comment on what the mix should be or what it implies for margins.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY25 revenue | Relatively flat versus prior expectation of moderate growth | FY25 |
| FY26 growth | Business to regain momentum with high growth, driven by new facilities and CMS commercial launches | FY26 |
| Unit 3 production block | Complete construction by FY25; commence commercial production | FY26 |
| Difelikefalin DMF filing | File the DMF | Next year (FY26) |
| Tirzepatide DMF filing | File the DMF | Year after next (FY27) |
| CMS revenue share | Cross 50% share | Next couple of years |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Total income | ₹315.2 cr, vs ₹420.8 cr in Q2 FY24 |
| EBITDA | ₹65.7 cr, margin 20.8% vs ₹140.3 cr in Q2 FY24 |
| Gross margin | 56.3%, vs 59.8% in Q2 FY24 |
| Profit after tax | ₹32 cr, vs ₹89.1 cr in Q2 FY24 |
| EPS | ₹24.9 per share |
| H1FY25 revenue | ₹759.6 cr, degrowth of 3.3% vs H1FY24 |
| H1FY25 EBITDA | ₹194.3 cr, vs ₹239.6 cr in H1FY24 |
| FY25 revenue outlook | Flat vs FY24, revised from moderate growth |
| CMS revenues | ₹132 cr, driven by commercial segment molecules |
| CMS commercial APIs | Increased by 1, following FDA approval of an NCE API |
| Working capital | 112 days to sales |
| Free cash flow (H1FY25) | ₹45.8 cr |
| Net debt | Negative ₹94.3 cr |
| Capital spend (H1FY25) | ₹103.5 cr, on facility upgradation |
| R&D scientist headcount | ~360, unchanged over last 2 years |